Seeking Alpha

AstraZeneca's (AZN -1.8%) purchase of Ardea Biosciences (RDEA +51.5%) may be the first in a...

AstraZeneca's (AZN -1.8%) purchase of Ardea Biosciences (RDEA +51.5%) may be the first in a series of deals for the company. The drug developer is considering buying other late-stage assets outside its research and development focus on cancer, diabetes and gastrointestinal ailments, in an effort to counter looming generic competition.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)